|
|
News Breaks
|
January 5, 2010
|
| 06:05 EDT |  | MNOV |
| theflyonthewall.com: | MedicNova extends conversion deadline | | MediciNova announced that it has extended the deadline for submission of conversion notices for the first conversion date for its floating rate secured convertible notes due 2011 from December 31, 2009 to January 11, 2010. At the closing of the acquisition of Avigen by a wholly-owned subsidiary of MediciNova, MediciNova issued $29,445,824.82 of Convertible Notes as part of the merger consideration. Under the terms of the indenture governing the Convertible Notes, holders may submit conversion notices, which are irrevocable, on a monthly basis instructing the trustee to convert such Convertible Notes into shares of MediciNova's common stock at an initial conversion price of $6.80 per share. :theflyonthewall.com |
|
|
News For MNOV From The Last 14 Days Check below for free stories on MNOV the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 3, 2012
|
| 12:00 EDT |  | MNOV |
|
|
February 2, 2012
|
| 12:00 EDT | | MNOV |
| | 10:00 EDT | | MNOV |
| theflyonthewall.com: | MedicNova rises 29.6% | | MedicNova is up 29.6%, or 56c, to $2.45 :theflyonthewall.com |
|
|
February 1, 2012
|
| 06:31 EDT | | MNOV |
| theflyonthewall.com: | MedicNova receives notice of patent allowance for a method of treating MS | | MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market and the Jasdaq Market of the Osaka Securities Exchange (4875), announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers the use of ibudilast for the treatment of progressive forms of multiple sclerosis. Ibudilast (MN-166), is the company's lead drug development candidate for certain neurological conditions, including progressive multiple sclerosis, neuropathic pain, and drug addiction. :theflyonthewall.com |
|
|
|
|
|
Subscribe for More Information